Nasal drug delivery has moved far beyond familiar allergy sprays, now supporting life-saving rescue therapies, complex systemic treatments and investigational nose-to-brain approaches. As this evolution and shift toward wider, more complex applications continue, so too will expectations for product quality and reliability.
Behind every successful nasal product sits a delicate balance of interdependent elements. Formulation, device, analytical testing and regulatory strategy must align to a single target product profile. When these decisions are made in isolation, development becomes slower, and more uncertain.
In this eBook, we explore what it takes to deliver high-performing nasal products in this environment, and how a coordinated, formulation-led approach helps reduce risk and move nasal programs forward with confidence.
Key takeaways:
- The forces shaping today’s nasal drug delivery landscape and the opportunities emerging across systemic, rescue and nose-to-brain applications
- The formulation-first approach that guides every decision from early feasibility through scale-up
- The device, analytical and human factors capabilities that support targeted deposition, reliable performance and patient-centric design
- The manufacturing strength and integrated model at Kindeva that support more efficient development and accelerate progress
Download the eBook to discover a more coordinated approach to nasal development.
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
HFA152a green propellant capabilities
With evolving regulations and a growing push for sustainability, switching pressurized metered-dose inhalers (pMDIs) to green propellants is becoming increasingly essential. One of the most promising low global warming potential (GWP) options is HFA152a. In this white paper, we share insights on transitioning to HFA152a. Download your copy to discover: An overview of sustainability regulations […]
Learn More
Leading the way in low-GWP propellants
As regulations surrounding inhalation device sustainability evolve, we help you streamline the process of transitioning to low global warming potential (GWP) propellants. Clinical supply for green propellants HFA152a and HFO1234ze is already available, with commercial scale available this year and plans for further expansion. Download this information sheet to dive deeper into our low-GWP propellant […]
Learn More
Opportunities and considerations for inhaled biologics
Respiratory biologics is an emerging area in pharmaceutical development, accounting for approximately 10% of biologics currently in the pipeline. These innovative treatments offer significant benefits across various therapeutic areas. Gain deeper insights into the development of inhaled biologics with this comprehensive presentation by experts from Kindeva Drug Delivery, Aerogen Pharma, and Cystetic Medicines. Highlights include: […]
Learn More
Pulmonary & nasal delivery capabilities
Get an overview of our pulmonary & nasal delivery capabilities, including: Customized approach to determining the right device for your drug Pulmonary & nasal platform technologies: pressurized metered-dose inhaler (pMDI), dry power inhaler (DPI), soft-mist inhaler (SMI), nebulizer, and nasal spray Green propellant innovations Experience bringing complex generics to market Expansive capabilities across state-of-the-art facilities […]
Learn More
Optimizing spray formation of low GWP metered dose inhalers – Unlocking product performance understanding
In response to growing concerns about sustainability, switching to more environmentally friendly pMDI propellants has become a high priority for the pharmaceutical industry. Since inhalation devices contribute 3% of global emissions, this is an important step. In addition to being a part of a greener future, transitioning to a low GWP propellant now positions companies […]
Learn MoreOptimizing spray formation of low GWP metered dose inhalers – unlocking product performance understanding
Thank you for attending the webinar for Benjamin Myatt, R&D Staff Scientist at Kindeva, and Daniel Duke, Senior Lecturer in the Department of Mechanical & Aerospace Engineering at Monash University. This session explored key issues related to spray formation and product development for MDI using green propellants. Key Takeaways: The differences in pMDI propellant properties […]
Learn More
Missed ss at DDL? Unlock pulmonary & nasal insights with our presentations
Kindeva Drug Delivery presented cutting-edge advancements in pulmonary & nasal development and manufacturing at the Drug Delivery to the Lungs (DDL) conference on December 6-8, 2023. Across eight posters and podium presentations, we highlighted strategies for switching to green propellant formulations while preserving product performance, among a variety of other topics. If you missed any […]
Learn More
Green propellants: The impact of proposed regulations
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.